Charles Schwab Investment Management Inc Acadia Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,275,279 shares of ACAD stock, worth $18.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,275,279

Previous 1,189,043 7.25%

Holding current value

$18.9 Million

Previous $22 Million 5.74%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$14.62 - $18.42 $1.26 Million - $1.59 Million	86,236 Added 7.25%	1,275,279 $20.7 Million
Q1 2024 May 08, 2024	BUY	$17.79 - $30.86 $1.09 Million - $1.89 Million	61,136 Added 5.42%	1,189,043 $22 Million
Q4 2023 Feb 06, 2024	BUY	$20.78 - $31.77 $1.14 Million - $1.74 Million	54,814 Added 5.11%	1,127,907 $35.3 Million
Q3 2023 Nov 08, 2023	BUY	$20.84 - $33.47 $1.91 Million - $3.07 Million	91,641 Added 9.34%	1,073,093 $22.4 Million
Q2 2023 Aug 09, 2023	BUY	$17.8 - $25.65 $216,412 - $311,852	12,158 Added 1.25%	981,452 $23.5 Million
Q1 2023 May 11, 2023	SELL	$16.32 - $20.92 $40,147 - $51,463	-2,460 Reduced 0.25%	969,294 $18.2 Million
Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $270,936 - $355,460	19,080 Added 2.0%	971,754 $15.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $501,088 - $648,822	35,513 Added 3.87%	952,674 $15.6 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $255,165 - $533,865	-19,613 Reduced 2.09%	917,161 $12.9 Million
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $1.13 Million - $1.48 Million	53,773 Added 6.09%	936,774 $22.7 Million
Q4 2021 Feb 11, 2022	BUY	$16.79 - $27.09 $1.04 Million - $1.68 Million	61,899 Added 7.54%	883,001 $20.6 Million
Q3 2021 Nov 16, 2021	SELL	$15.78 - $24.77 $4.55 Million - $7.14 Million	-288,267 Reduced 25.98%	821,102 $13.6 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $5.1 Million - $7.21 Million	262,806 Added 31.04%	1,109,369 $27.1 Million
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $270,391 - $594,276	-10,807 Reduced 1.26%	846,563 $21.8 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $1.57 Million - $2.17 Million	-38,177 Reduced 4.26%	857,370 $45.8 Million
Q3 2020 Nov 13, 2020	BUY	$36.42 - $57.0 $5.84 Million - $9.15 Million	160,482 Added 21.83%	895,547 $36.9 Million
Q2 2020 Aug 14, 2020	SELL	$39.26 - $52.73 $4.24 Million - $5.69 Million	-107,893 Reduced 12.8%	735,065 $35.6 Million
Q1 2020 May 15, 2020	BUY	$31.65 - $46.87 $3.55 Million - $5.26 Million	112,135 Added 15.34%	842,958 $35.6 Million
Q4 2019 Feb 07, 2020	BUY	$36.21 - $51.4 $3.45 Million - $4.89 Million	95,151 Added 14.97%	730,823 $31.3 Million
Q3 2019 Nov 08, 2019	SELL	$22.22 - $44.01 $2.12 Million - $4.2 Million	-95,320 Reduced 13.04%	635,672 $22.9 Million
Q2 2019 Aug 09, 2019	BUY	$23.32 - $28.12 $677,002 - $816,351	29,031 Added 4.14%	730,992 $19.5 Million
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $1.8 Million - $3.04 Million	111,155 Added 18.81%	701,961 $18.8 Million
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $255,296 - $408,617	17,828 Added 3.11%	590,806 $9.55 Million
Q3 2018 Nov 13, 2018	SELL	$13.03 - $21.81 $1.71 Million - $2.86 Million	-131,184 Reduced 18.63%	572,978 $11.9 Million
Q2 2018 Aug 08, 2018	BUY	$15.07 - $22.34 $3.89 Million - $5.76 Million	257,871 Added 57.78%	704,162 $10.8 Million
Q1 2018 May 07, 2018	SELL	$22.47 - $32.33 $99,272 - $142,833	-4,418 Reduced 0.98%	446,291 $10 Million
Q4 2017 Jan 17, 2018	BUY	$26.84 - $39.14 $754,311 - $1.1 Million	28,104 Added 6.65%	450,709 $13.6 Million
Q3 2017 Nov 13, 2017	BUY	$29.49 - $38.37 $12.5 Million - $16.2 Million	422,605	422,605 $15.9 Million

Others Institutions Holding ACAD

# of Institutions

288

Shares Held

161M

Call Options Held

723K

Put Options Held

257K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Acadia Pharmaceuticals Inc Transaction History